In fact, it has been reported that only 0.4% of lung adenocarcinoma patients with EGFR mutations have IP; thus, there are few situations in real-world clinical practice where we wonder whether EGFR-TKIs should be administered to these populations [37]. The gene discussed is EGFR; the disease is lung adenocarcinoma.